Atlas Trials

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

Clinical trial NCT06268327 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06268327
Sponsor
Assiut University
Status
NOT_YET_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2024-04-30
Primary completion
2025-10-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.